Related Experiment Video
Updated: Sep 15, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Antidepressants and risk of inflammatory bowel disease: A drug-target Mendelian randomization study
Ji-Lin Wang1, Ye Hu2, Zhi-Jun Cao1
1Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background:
Previous studies have found that antidepressants could reduce the risk of IBD, but the results are controversial. Therefore, a drug-target Mendelian randomization was applied to explore the casual relationship between antidepressants and IBD, aiming to identify new preventive uses for the drugs.
Methods:
Target genes corresponding to classic SSRI drugs were obtained from the DrugBank database. eQTL Data was collected from the eQTLGen Consortium database. GWAS data for IBD were retrieved from the FinnGen dataset. The IVW-MR and SMR methods were used for the analysis. Heterogeneity was assessed using the Cochran's Q test, and sensitivity analyses was conducted to verify the reliability of the results.
Results:
The IVW-MR analysis indicated a significant correlation between SIGMAR1 and risk of IBD, CD and UC. The OR with 95%CI for IBD was 0.925 (0.885-0.968), for CD was 0.91(0.845-0.979), for UC was 0.942(0.895-0.991). The SMR analysis indicated a significant correlation between SLC29A4 and risk of IBD, CD and UC. The OR with 95%CI was 1.524(1.265-1.784) for IBD, 1.767(1.343-2.19) for CD and 1.613(1.316-1.909) for UC. There were no significant genetic associations between serotonin concentration and IBD. The sensitivity analysis suggested no evidence of heterogeneity or pleiotropy among the reported results.
Conclusion:
Activation of SIGMAR1 could reduce the risk of IBD, while activation of SLC29A4 could increase the risk of IBD. Further research is warranted to fully understand the potential role of SSRIs targeted genes in the development and progression of IBD.
More Related Videos
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF